Structural valve deterioration of the Labcor Dokimos aortic prosthesis: a single-centre experience
- PMID: 34687533
- PMCID: PMC10634400
- DOI: 10.1093/icvts/ivab286
Structural valve deterioration of the Labcor Dokimos aortic prosthesis: a single-centre experience
Abstract
Objectives: The goal of this study was to assess the performance and incidence of the deterioration of the Labcor Dokimos bioprosthetic aortic valve.
Methods: We performed a retrospective medical chart review of 116 patients who underwent surgical aortic valve replacement with the Labcor Dokimos aortic valve between 2010 and 2018. Abstracted data included patient demographic and echocardiographic data. Patients were divided into 2 groups: patients with structural valve deterioration (SVD) and patients without SVD.
Results: Among the patients with complete follow-up (n = 95), 10 patients were excluded because they died within a year; 85 patients were included in the final analysis. Of the 85 patients, 32 (38%) developed SVD; 22 (26%) had severe SVD, 15 (18%) of whom underwent reintervention. The most common aetiology of SVD was severe central aortic regurgitation, which was detected in 91% of the patients who had severe SVD. The average time from operation to severe SVD was 4.7 years with a minimum of 1.5 years and a maximum of 7.9 years.
Conclusions: Bioprosthetic aortic valve deterioration due to severe aortic regurgitation is common and occurs early with the Labcor Dokimos valve. This occurrence needs to be furthered investigated in larger registries.
Keywords: Education cardiac; Transcatheter valve therapy; Valve disease.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.
Figures
References
-
- Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:e57-185–2488. - PubMed
-
- Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. ; ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739–91. - PubMed
-
- Dvir D, Bourguignon T, Otto CM, Hahn RT, Rosenhek R, Webb JG et al. ; VIVID (Valve in Valve International Data) Investigators. Standardized definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves. Circulation 2018;137:388–99. - PubMed
-
- Sénage T, Le Tourneau T, Foucher Y, Pattier S, Cueff C, Michel M et al. Early structural valve deterioration of Mitroflow aortic bioprosthesis: mode, incidence, and impact on outcome in a large cohort of patients. Circulation 2014;130:2012–20. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
